{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:57:08Z","timestamp":1790989028846,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373348"],"award-info":[{"award-number":["82373348"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82572973"],"award-info":[{"award-number":["82572973"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2022J011427"],"award-info":[{"award-number":["2022J011427"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007289","name":"Nanjing Medical University","doi-asserted-by":"publisher","award":["TZKY20240302"],"award-info":[{"award-number":["TZKY20240302"]}],"id":[{"id":"10.13039\/501100007289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007289","name":"Nanjing Medical University","doi-asserted-by":"publisher","award":["TZKY20220204"],"award-info":[{"award-number":["TZKY20220204"]}],"id":[{"id":"10.13039\/501100007289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007289","name":"Nanjing Medical University","doi-asserted-by":"publisher","award":["TZKY20220205"],"award-info":[{"award-number":["TZKY20220205"]}],"id":[{"id":"10.13039\/501100007289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.bbadis.2026.168447","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:53:21Z","timestamp":1788364401000},"page":"168447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defactinib inhibits focal adhesion kinase to attenuate pancreatic cancer growth via PI3K\/AKT pathway modulation"],"prefix":"10.1016","volume":"1873","author":[{"given":"Hui-Deng","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Yin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Xing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui-Ni","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Feng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Guang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bbadis.2026.168447_bb0005","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.21873\/anticanres.18226","article-title":"Metabolic reprogramming and chemoresistance in pancreatic ductal adenocarcinoma: mechanisms and therapeutic strategies","volume":"46","author":"Ahn","year":"2026","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168447_bb0010","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/OP.24.00279","article-title":"Novel therapies for pancreatic cancer","volume":"21","author":"Chung","year":"2025","journal-title":"JCO Oncol. Pract."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168447_bb0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","article-title":"Therapeutic developments in pancreatic cancer","volume":"21","author":"Hu","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168447_bb0020","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s13402-024-00970-6","article-title":"Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma","volume":"47","author":"Li","year":"2024","journal-title":"Cell. Oncol. (Dordr)"},{"issue":"13","key":"10.1016\/j.bbadis.2026.168447_bb0025","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.3390\/cancers14133293","article-title":"The desmoplastic stroma of pancreatic cancer: multilayered levels of heterogeneity, clinical significance, and therapeutic opportunities","volume":"14","author":"Masugi","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168447_bb0030","article-title":"Advances in pancreatic cancer early diagnosis, prevention, and treatment: the past, the present, and the future","volume":"76","author":"Mannucci","year":"2026","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168447_bb0035","first-page":"61","article-title":"Targeting pancreatic ductal adenocarcinoma (PDAC)","volume":"55","author":"Parrasia","year":"2021","journal-title":"Cell. Physiol. Biochem."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168447_bb0040","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.3390\/cimb45030124","article-title":"Molecular research in pancreatic cancer: small molecule inhibitors, their mechanistic pathways and beyond","volume":"45","author":"Shetu","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"issue":"2","key":"10.1016\/j.bbadis.2026.168447_bb0045","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1039\/C9MD00447E","article-title":"Small molecule inhibitors in pancreatic cancer","volume":"11","author":"Sun","year":"2020","journal-title":"RSC Med. Chem."},{"issue":"16","key":"10.1016\/j.bbadis.2026.168447_bb0050","doi-asserted-by":"crossref","DOI":"10.1172\/JCI191939","article-title":"KRAS: the Achilles' heel of pancreas cancer biology","volume":"135","author":"Drizyte-Miller","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.bbadis.2026.168447_bb0055","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41575-021-00463-z","article-title":"The pancreatic cancer genome revisited","volume":"18","author":"Hayashi","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168447_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100745","article-title":"Targeting KRAS(G12C) in colorectal cancer: the beginning of a new era","volume":"8","author":"Ciardiello","year":"2023","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.bbadis.2026.168447_bb0065","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1158\/2159-8290.CD-22-0044","article-title":"Coordinated transcriptional and catabolic programs support iron-dependent adaptation to RAS-MAPK pathway inhibition in pancreatic cancer","volume":"12","author":"Ravichandran","year":"2022","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.bbadis.2026.168447_bb0070","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.bbadis.2026.168447_bb0075","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1016\/j.apsb.2023.07.018","article-title":"A high-throughput Gaussia luciferase reporter assay for screening potential gasdermin E activators against pancreatic cancer","volume":"13","author":"Liu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.bbadis.2026.168447_bb0080","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-25-0478","article-title":"HMGCS1 as a potential mediator of resistance to EZH2 inhibition via ferroptosis mediated by PI3K\/AKT\/mTOR pathway in the pancreatic neuroendocrine neoplasms","volume":"33","author":"He","year":"2026","journal-title":"Endocr. Relat. Cancer"},{"issue":"8","key":"10.1016\/j.bbadis.2026.168447_bb0085","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1158\/2159-8290.CD-25-1627","article-title":"Senescent cancer-associated fibroblasts drive early-stage lymph node metastasis in pancreatic cancer through lactate-mediated metabolic-epigenetic rewiring","volume":"16","author":"Zhou","year":"2026","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.bbadis.2026.168447_bb0090","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.ccell.2025.06.021","article-title":"Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer","volume":"43","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168447_bb0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00066-020-01666-0","article-title":"FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro","volume":"197","author":"Mohamed","year":"2021","journal-title":"Strahlenther. Onkol."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168447_bb0100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/gutjnl-2022-327927","article-title":"FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer","volume":"73","author":"Canel","year":"2023","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168447_bb0105","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2539442","article-title":"Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8(+) T cell infiltration","volume":"14","author":"Shi","year":"2025","journal-title":"Oncoimmunology"},{"issue":"14","key":"10.1016\/j.bbadis.2026.168447_bb0110","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.261723","article-title":"Focal adhesion kinase signaling - tumor vulnerabilities and clinical opportunities","volume":"137","author":"Schlaepfer","year":"2024","journal-title":"J. Cell Sci."},{"issue":"6","key":"10.1016\/j.bbadis.2026.168447_bb0115","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/13543784.2024.2348068","article-title":"Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study","volume":"33","author":"Gao","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bbadis.2026.168447_bb0120","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.47327","article-title":"FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy","volume":"8","author":"Diaz Osterman","year":"2019","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.bbadis.2026.168447_bb0125","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","article-title":"A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors","volume":"33","author":"Jones","year":"2015","journal-title":"Investig. New Drugs"},{"issue":"24","key":"10.1016\/j.bbadis.2026.168447_bb0130","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1158\/1078-0432.CCR-22-0308","article-title":"Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: a phase I dose escalation and expansion study","volume":"28","author":"Wang-Gillam","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2026.168447_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113116","article-title":"Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment","volume":"151","author":"Wu","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168447_bb0140","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12672-021-00449-y","article-title":"Focal adhesion kinase inhibitors, a heavy punch to cancer","volume":"12","author":"Wu","year":"2021","journal-title":"Discov. Oncol."},{"issue":"12","key":"10.1016\/j.bbadis.2026.168447_bb0145","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.3390\/ijms23126381","article-title":"The development of FAK inhibitors: a five-year update","volume":"23","author":"Spallarossa","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bbadis.2026.168447_bb0150","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1080\/1061186X.2024.2385557","article-title":"Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: synthesis, mechanistic insights and promising antitumor and safety profile","volume":"32","author":"Pecoraro","year":"2024","journal-title":"J. Drug Target."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168447_bb0155","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00280-016-3010-1","article-title":"A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors","volume":"77","author":"Shimizu","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"10","key":"10.1016\/j.bbadis.2026.168447_bb0160","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/s41416-019-0452-3","article-title":"A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours","volume":"120","author":"Mak","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.bbadis.2026.168447_bb0165","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/ijms23031726","article-title":"FAK in cancer: from mechanisms to therapeutic strategies","volume":"23","author":"Chuang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168447_bb0170","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","article-title":"Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity","volume":"163","author":"Serrels","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168447_bb0175","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12282-025-01792-6","article-title":"Targeting focal adhesion kinase inhibits cell migration and non-angiogenic vascularization in malignant breast cancer","volume":"33","author":"Masuyama","year":"2026","journal-title":"Breast Cancer"},{"issue":"4","key":"10.1016\/j.bbadis.2026.168447_bb0180","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/13543784.2020.1740680","article-title":"FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials","volume":"29","author":"Mohanty","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168447_bb0185","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/s12885-022-09520-5","article-title":"CT-707 overcomes hypoxia-mediated sorafenib resistance in hepatocellular carcinoma by inhibiting YAP signaling","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Cancer"},{"issue":"22","key":"10.1016\/j.bbadis.2026.168447_bb0190","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.1158\/0008-5472.CAN-07-2667","article-title":"Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma","volume":"67","author":"Halder","year":"2007","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.bbadis.2026.168447_bb0195","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.3390\/molecules26144250","article-title":"Drug discovery targeting focal adhesion kinase (FAK) as a promising cancer therapy","volume":"26","author":"Pang","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bbadis.2026.168447_bb0200","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2019.10.033","article-title":"Phase 2 study of the focal adhesion kinase inhibitor Defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer","volume":"139","author":"Gerber","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bbadis.2026.168447_bb0205","article-title":"Phase II study of defactinib (VS6063) in patients with tumors with NF2 loss: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol U","volume":"8","author":"Zauderer","year":"2024","journal-title":"JCO Precis. Oncol."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168447_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2026.104635","article-title":"Avutometinib and Defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer","volume":"36","author":"Hayward","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"18","key":"10.1016\/j.bbadis.2026.168447_bb0215","doi-asserted-by":"crossref","first-page":"18322","DOI":"10.18632\/aging.103698","article-title":"A two-gene-based prognostic signature for pancreatic cancer","volume":"12","author":"Zhou","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"21","key":"10.1016\/j.bbadis.2026.168447_bb0220","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.7150\/jca.47629","article-title":"Development and validation of a metastasis-related gene signature for predicting the overall survival in patients with pancreatic ductal adenocarcinoma","volume":"11","author":"Wu","year":"2020","journal-title":"J. Cancer"},{"issue":"5","key":"10.1016\/j.bbadis.2026.168447_bb0225","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1007\/s10528-023-10625-0","article-title":"Machine learning developed a MYC expression feature-based signature for predicting prognosis and chemoresistance in pancreatic adenocarcinoma","volume":"62","author":"Dong","year":"2024","journal-title":"Biochem. Genet."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168447_bb0230","first-page":"75","article-title":"Ablative therapies of pancreatic neoplasms","volume":"112","author":"Crin\u00f2","year":"2021","journal-title":"Recenti Prog. Med."},{"issue":"770","key":"10.1016\/j.bbadis.2026.168447_bb0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado2402","article-title":"Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy","volume":"16","author":"Liu","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168447_bb0240","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1038\/s41467-021-27038-5","article-title":"Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation","volume":"12","author":"Ryzhakov","year":"2021","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bbadis.2026.168447_bb0245","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s40265-025-02215-8","article-title":"Avutometinib and defactinib: first approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.bbadis.2026.168447_bb0250","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/mc.23273","article-title":"Focal adhesion kinase (FAK) inhibitor-Defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K\/AKT axis and downstream molecular network","volume":"60","author":"Zhang","year":"2021","journal-title":"Mol. Carcinog."},{"issue":"16","key":"10.1016\/j.bbadis.2026.168447_bb0255","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3390\/cells14161250","article-title":"DIRAS3 inhibits ovarian cancer cell growth by blocking the fibronectin-mediated integrin \u03b21\/FAK\/AKT signaling pathway","volume":"14","author":"Guo","year":"2025","journal-title":"Cells"},{"issue":"16","key":"10.1016\/j.bbadis.2026.168447_bb0260","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1158\/0008-5472.CAN-23-3638","article-title":"FBXO32 stimulates protein synthesis to drive pancreatic cancer progression and metastasis","volume":"84","author":"Su","year":"2024","journal-title":"Cancer Res."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926003133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926003133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:22:31Z","timestamp":1790986951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443926003133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S0925443926003133"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168447","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defactinib inhibits focal adhesion kinase to attenuate pancreatic cancer growth via PI3K\/AKT pathway modulation","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"168447"}}